Journal article icon

Journal article

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Abstract:

PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduct...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1182/bloodadvances.2020003314

Authors


More by this author
Role:
Author
ORCID:
0000-0002-3422-1309
More from this funder
Name:
Medical Research Council
Grant:
MR/L006340/1
MC_UU_00016/1
Publisher:
American Society of Hematology
Journal:
Blood Advances More from this journal
Volume:
4
Issue:
22
Pages:
5825-5835
Publication date:
2020-11-24
Acceptance date:
2020-10-14
DOI:
EISSN:
2473-9537
ISSN:
2473-9529
Pmid:
33232476
Language:
English
Keywords:
Pubs id:
1147843
Local pid:
pubs:1147843
Deposit date:
2021-01-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP